| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
796.44(B) |
| Last
Volume: |
1,747,701 |
Avg
Vol: |
3,278,293 |
| 52
Week Range: |
$434.7 - $815.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
505,762 |
1,375,762 |
3,014,918 |
5,975,430 |
| Total Sell Value |
$409,104,400 |
$1,016,789,780 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
10 |
22 |
49 |
89 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Walker Karen |
Director |
– • – |
2019-07-15 |
4 |
A |
$108.47 |
$12,366 |
D/D |
114 |
827 |
|
- |
|
| Smiley Joshua L |
SVP and CFO |
• – – |
2019-07-15 |
4 |
AB |
$108.47 |
$20,067 |
D/D |
185 |
30,595 |
|
- |
|
| Pusey Leigh Ann |
SVP, Corp. Affairs & Comm. |
• – – |
2019-07-05 |
4 |
D |
$114.42 |
$123,574 |
D/D |
(1,080) |
2,956 |
|
- |
|
| Pusey Leigh Ann |
SVP, Corp. Affairs & Comm. |
• – – |
2019-07-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,394 |
4,036 |
|
- |
|
| Walker Karen |
Director |
– • – |
2019-06-17 |
4 |
A |
$113.40 |
$9,866 |
D/D |
87 |
713 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2019-06-17 |
4 |
A |
$113.40 |
$2,041 |
D/D |
18 |
54,444 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2019-06-17 |
4 |
A |
$113.40 |
$13,608 |
D/D |
120 |
8,792 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2019-06-17 |
4 |
A |
$113.40 |
$10,886 |
D/D |
96 |
44,296 |
|
- |
|
| Smiley Joshua L |
SVP and CFO |
• – – |
2019-06-05 |
4 |
B |
$118.03 |
$50,281 |
D/D |
426 |
30,410 |
2.74 |
- |
|
| Harrington Michael J |
Senior VP and General Counsel |
• – – |
2019-06-03 |
4 |
AS |
$116.72 |
$1,867,520 |
D/D |
(16,000) |
110,300 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2019-05-20 |
4 |
A |
$116.23 |
$10,926 |
D/D |
94 |
43,952 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2019-05-20 |
4 |
A |
$116.23 |
$13,599 |
D/D |
117 |
8,624 |
|
- |
|
| Walker Karen |
Director |
– • – |
2019-05-20 |
4 |
A |
$116.23 |
$19,875 |
D/D |
171 |
623 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2019-05-20 |
4 |
A |
$116.23 |
$1,976 |
D/D |
17 |
54,366 |
|
- |
|
| Shaw Christi |
SVP and Pres., Lilly Bio-Meds |
• – – |
2019-05-03 |
4/A |
AS |
$117.08 |
$828,575 |
D/D |
(7,077) |
500 |
|
- |
|
| Shaw Christi |
SVP and Pres., Lilly Bio-Meds |
• – – |
2019-05-03 |
4 |
AS |
$117.08 |
$887,570 |
D/D |
(7,577) |
0 |
|
- |
|
| Shaw Christi |
SVP and Pres., Lilly Bio-Meds |
• – – |
2019-05-01 |
4 |
D |
$117.04 |
$722,488 |
D/D |
(6,173) |
7,577 |
|
- |
|
| Shaw Christi |
SVP and Pres., Lilly Bio-Meds |
• – – |
2019-05-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,750 |
13,750 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2019-04-15 |
4 |
A |
$124.08 |
$1,985 |
D/D |
16 |
54,349 |
|
- |
|
| Walker Karen |
Director |
– • – |
2019-04-15 |
4 |
A |
$124.08 |
$9,926 |
D/D |
80 |
452 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2019-04-15 |
4 |
A |
$124.08 |
$10,671 |
D/D |
86 |
8,507 |
|
- |
|
| Marram Ellen R |
Director |
– • – |
2019-04-15 |
4 |
A |
$124.08 |
$6,824 |
D/D |
55 |
56,645 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2019-04-15 |
4 |
A |
$124.08 |
$10,919 |
D/D |
88 |
43,858 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2019-04-12 |
4 |
AS |
$124.65 |
$1,246,500 |
D/D |
(10,000) |
57,806 |
|
- |
|
| Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
• – – |
2019-04-12 |
4 |
AS |
$125.15 |
$592,585 |
D/D |
(4,735) |
22,085 |
|
- |
|
1437 Records found
|
|
Page 28 of 58 |
|
|
1.33 (0.16%) 
